Fig. 4: Diminished viral rebound over repeated chidamide administrations after M10 CAR-T treatment. | Cell Discovery

Fig. 4: Diminished viral rebound over repeated chidamide administrations after M10 CAR-T treatment.

From: Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: a phase I, multicenter, single-arm, open-label study

Fig. 4

Panels show plasma HIV-1 RNA of study participants after M10 CAR-T infusions. The adoptive transfer of M10 CAR-T cells was performed on Day 0 followed by double administrations of chidamide on Day 3 and Day 10 (shown as black arrows in the panels). All the subjects completed the full two courses of treatment, comprising two doses of chidamide per course, except for Subject 003, who missed the second dose of chidamide during the first course due to personal reasons. Blue shading represents a decline in viral rebound over repeated stimulation, while red shading represents an increase. The limit of detection of HIV-1 RNA levels in this assay is 20 copies/mL (shown as dashed gray lines). Timepoints with an undetectable plasma HIV-1 RNA is indicated by white triangles.

Back to article page